secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001828185-24-000007
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio FY2023 net loss $73.3M, revenue drops to $0.8M, cash down to $142.1M
--------------------------------------------------------------------------------

- Net loss of $73.3M ($1.91 per share) vs net income of $5.3M in 2022; revenue fell to $0.8M from $44.7M on lower Vaxzevria royalties.
- Cash and equivalents $142.1M at Dec 31, 2023, down from $194.4M; operating cash burn $50.9M.
- R&D expenses rose to $44.9M (+$2.5M); G&A surged to $39.8M (+$33.4M) primarily due to a $7.6M foreign exchange loss.
- Pipeline: positive HBV VTP-300 Phase 2 data; HPV VTP-200 APOLLO trial final results expected Q2 2024; celiac VTP-1000 Phase 1 initiation planned Q2 2024.
- Secured up to $35M from CEPI for MERS candidate VTP-500; renamed from Vaccitech to Barinthus in Nov 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/0001828185-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/brns-20240320.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer